Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293230173> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4293230173 abstract "<h3>Background and importance</h3> Hidradenitis suppurativa (HS) is a skin condition, especially in areas of constant friction, characterised by painful subdermal lesions that generally worsen over time and that have serious repercussions on the quality of life of patients. Risankizumab is a new anti-IL-23 (IgG1) monoclonal antibody authorised and used for moderate to severe psoriasis and with a potential effect on HS refractory to adalimumab (anti-tumour necrosis factor alpha (anti-TNFα)). <h3>Aim and objectives</h3> To evaluate the evolution and response of risankizumab after combined treatment with adalimumab and resorcinol 15% cream in a severe and refractory HS in a 63-year-old man during 24 months of treatment. <h3>Material and methods</h3> To evaluate the efficacy of risankizumab, the clinical response was monitored through the resolution of the lesions in the affected areas at 1, 3 and 6 months. <h3>Results</h3> The patient was diagnosed in early 2019. After starting treatment with adalimumab (loading dose: 160 mg day 0, 80 mg day 14 and 40 mg weekly) for 2 years, adjuvant treatment with topical resorcinol 15% (twice a day) was started for the last 6 months. Finally it was decided to start treatment with risankizumab subcutaneous in January 2021 (loading dose: 150 mg day 0, 150 mg day 28 and 150 mg after every 12 weeks). Only adalimumab stopped before starting risankizumab. After 1 month of dual treatment (risankizumab and resorcinol), the patient showed a significant improvement in the skin lesions produced by HS. Two cycles after starting risankizumab the lesions had resolved by 80%. The patient was followed for the first 6 months with risankizumab. <h3>Conclusion and relevance</h3> Risankizumab has proven to be a therapeutic alternative for the treatment of HS beyond glucocorticoids, methotrexate and anti-TNFα. The combination with resorcinol 15% cream seems to have enhanced the effect of risankizumab, although larger population studies are needed to establish itself as a therapeutic alternative. The role of the hospital pharmacists was to advise the Local Commission on the choice of anti-IL-23 among risankizumab, guselkumab and tildrakizumab, according to the reports reported. This is the first documented case in Andalusia, Spain. <h3>References and/or acknowledgements</h3> 1. Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. <i>JAMA</i> 2017;<b>318</b>:2019–2032. Special thanks to the Dermatology Unit. <h3>Conflict of interest</h3> No conflict of interest" @default.
- W4293230173 created "2022-08-27" @default.
- W4293230173 creator A5016109685 @default.
- W4293230173 creator A5035737264 @default.
- W4293230173 creator A5043085911 @default.
- W4293230173 creator A5063902383 @default.
- W4293230173 creator A5076591853 @default.
- W4293230173 date "2022-03-01" @default.
- W4293230173 modified "2023-09-28" @default.
- W4293230173 title "4CPS-089 Risankizumab in refractory hidradenitis suppurativa to anti-TNFα: a case report" @default.
- W4293230173 doi "https://doi.org/10.1136/ejhpharm-2022-eahp.122" @default.
- W4293230173 hasPublicationYear "2022" @default.
- W4293230173 type Work @default.
- W4293230173 citedByCount "0" @default.
- W4293230173 crossrefType "proceedings-article" @default.
- W4293230173 hasAuthorship W4293230173A5016109685 @default.
- W4293230173 hasAuthorship W4293230173A5035737264 @default.
- W4293230173 hasAuthorship W4293230173A5043085911 @default.
- W4293230173 hasAuthorship W4293230173A5063902383 @default.
- W4293230173 hasAuthorship W4293230173A5076591853 @default.
- W4293230173 hasBestOaLocation W42932301731 @default.
- W4293230173 hasConcept C121332964 @default.
- W4293230173 hasConcept C126322002 @default.
- W4293230173 hasConcept C141071460 @default.
- W4293230173 hasConcept C142424586 @default.
- W4293230173 hasConcept C16005928 @default.
- W4293230173 hasConcept C178790620 @default.
- W4293230173 hasConcept C17991360 @default.
- W4293230173 hasConcept C185592680 @default.
- W4293230173 hasConcept C2776002364 @default.
- W4293230173 hasConcept C2779134260 @default.
- W4293230173 hasConcept C2780016452 @default.
- W4293230173 hasConcept C2780132546 @default.
- W4293230173 hasConcept C2780564577 @default.
- W4293230173 hasConcept C71924100 @default.
- W4293230173 hasConcept C87355193 @default.
- W4293230173 hasConcept C90924648 @default.
- W4293230173 hasConceptScore W4293230173C121332964 @default.
- W4293230173 hasConceptScore W4293230173C126322002 @default.
- W4293230173 hasConceptScore W4293230173C141071460 @default.
- W4293230173 hasConceptScore W4293230173C142424586 @default.
- W4293230173 hasConceptScore W4293230173C16005928 @default.
- W4293230173 hasConceptScore W4293230173C178790620 @default.
- W4293230173 hasConceptScore W4293230173C17991360 @default.
- W4293230173 hasConceptScore W4293230173C185592680 @default.
- W4293230173 hasConceptScore W4293230173C2776002364 @default.
- W4293230173 hasConceptScore W4293230173C2779134260 @default.
- W4293230173 hasConceptScore W4293230173C2780016452 @default.
- W4293230173 hasConceptScore W4293230173C2780132546 @default.
- W4293230173 hasConceptScore W4293230173C2780564577 @default.
- W4293230173 hasConceptScore W4293230173C71924100 @default.
- W4293230173 hasConceptScore W4293230173C87355193 @default.
- W4293230173 hasConceptScore W4293230173C90924648 @default.
- W4293230173 hasLocation W42932301731 @default.
- W4293230173 hasOpenAccess W4293230173 @default.
- W4293230173 hasPrimaryLocation W42932301731 @default.
- W4293230173 hasRelatedWork W2060916732 @default.
- W4293230173 hasRelatedWork W2067775822 @default.
- W4293230173 hasRelatedWork W2146549230 @default.
- W4293230173 hasRelatedWork W2170060483 @default.
- W4293230173 hasRelatedWork W2406538423 @default.
- W4293230173 hasRelatedWork W2441483125 @default.
- W4293230173 hasRelatedWork W2966329906 @default.
- W4293230173 hasRelatedWork W2977892511 @default.
- W4293230173 hasRelatedWork W3194765299 @default.
- W4293230173 hasRelatedWork W4250398814 @default.
- W4293230173 isParatext "false" @default.
- W4293230173 isRetracted "false" @default.
- W4293230173 workType "article" @default.